# High burden of non-adherence to blood pressure-lowering medications: meta-analysis of data from over 34,000 adults with hypertension in Sub-Saharan Africa

Leopold Ndemnge Aminde<sup>1, 2</sup>, Valirie Ndip Agbor<sup>3</sup>, Noah Takah Fongwen<sup>4, 5, 6</sup>, Calypse Ngwasiri<sup>7</sup>, Clovis Nkoke<sup>8,9</sup>, Miriam Nji<sup>10</sup>, Anastase Dzudie<sup>2,11,12</sup>, Aletta E. Schutte<sup>13,14</sup>

<sup>1</sup>Public Health & Economics Modelling Group, School of Medicine and Dentistry, Griffith University, Gold Coast, Australia.

<sup>2</sup>Non-communicable diseases Unit, Clinical Research Education, Networking & Consultancy (CRENC), Douala Cameroon.

<sup>3</sup>Clinical Trials Service and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.

<sup>4</sup>Ministry of Public Health, Yaounde, Cameroon.

<sup>5</sup>London School of Hygiene & Tropical Medicine, London, United Kingdom.

<sup>6</sup> Diagnostics Access, Africa Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.

<sup>7</sup>Ecole de Sante Publique, Universite Libre de Bruxelles, Brussels, Belgium.

<sup>8</sup>Faculty of Health Sciences, University of Buea, Buea, Cameroon.

<sup>9</sup>Cardiology Unit, Buea Regional Hospital, Buea, Cameroon.

<sup>10</sup>Northeast Georgia Medical Center, Braselton, USA.

<sup>11</sup> Faculty of Medicine & Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon.

<sup>12</sup>Cardiology Unit, Department of Medicine, Douala General Hospital, Douala, Cameroon.

<sup>13</sup>School of Population Health, University of New South Wales; The George Institute for Global Health, Sydney, Australia.

<sup>14</sup>Hypertension in Africa Research Team (HART)/MRC Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa.

**Correspondence:** Leopold N. Aminde, MD PhD FFPH. Public Health & Economics Modelling Group, School of Medicine & Dentistry, Griffith University, Gold Coast, QLD 4222, Australia. Email: <a href="mailto:laminde@griffith.edu.au">laminde@griffith.edu.au</a>.

Word count: abstract (249 words), main document (3,873 words)

## Abstract

**Introduction:** Non-adherence to blood pressure (BP)-lowering medication is a strong predictor of poor BP control. Sub-Saharan Africa (SSA) has extremely low BP control rates (~10%), but it is unclear what the burden of medication non-adherence among Africans with hypertension is. This systematic review estimated the prevalence and determinants of non-adherence to BP-lowering medications in SSA.

**Methods:** Multiple databases were searched from inception to 6 December 2023. Two reviewers performed independent screening, extraction, and quality assessment of studies. We pooled the prevalence estimates using random effects meta-analyses and summarized the determinants using a narrative synthesis.

**Results:** From the 1,307 records identified, we included 95 studies published between 1995 and 2023. The overall prevalence of non-adherence to BP-lowering medication among 34,102 people treated for hypertension in 27 countries was 43.5% (95% confidence interval 39.4 to 47.6;  $I^2 = 98.3\%$ ). There was no change in the prevalence of non-adherence over time. The burden of non-adherence varied by measurement method (p = 0.028) and by median age (38.8%, > 57 years vs. 47.9%,  $\leq$  57 years; p = 0.015). Socioeconomic and patient-related factors were the most frequent factors that influenced medication adherence. Active patient participation in management, accurate perceptions, and knowledge of hypertension and its treatment predicted good medication adherence, whereas high pill burden, medication cost, side effects, and comorbidities predicted poor adherence.

**Conclusions:** With the African population projected to increase from 1.4 to ~2.5 billion by 2050, targeted strategies are urgently needed to optimise medication adherence in people with hypertension in SSA.

Key words: Hypertension, medication adherence, determinants, systematic review, Africa

## Introduction

Hypertension is the leading risk factor for disease burden globally, affecting nearly 1.3 billion adults (1), and contributing to over 10.8 million deaths each year (2). The prevalence of hypertension in sub-Saharan (SSA) is high, affecting about one in three adults and one in two people aged 50 years and over (3-6). In SSA, over half of the women and two-thirds of the men with hypertension remain undiagnosed. This high burden of hypertension contrasts with very low treatment and control rates. A recent global analysis found that only 22–29% of adults diagnosed with hypertension in SSA are treated; of these, only 9% of men and 13% of women have their blood pressure (BP) controlled (1). Pharmacotherapy and lifestyle modification are the mainstay of BP control to prevent vascular complications including stroke, ischemic heart disease, chronic kidney disease, and dementia (3).

The World Health Organization (WHO) defines adherence as the extent to which a person's behaviour taking medication, following a diet, or executing lifestyle changes—corresponds with agreed recommendations from a healthcare provider (7). Non-adherence to medication has been identified as a major predictor of poorly controlled hypertension. Compared to people who are adherent to BP-lowering medication, those who are non-adherent are twice as likely to have sub-optimal BP control and to develop complications of hypertension (8). Understanding the extent of non-adherence and determinants is critical to the development of appropriate interventions to prevent the health and economic consequences for affected persons and health systems. Prior reviews exploring adherence to BP-lowering medication have been limited by either narrow inclusion time periods (9, 10), restricted to one adherence measurement method (9, 11), lacked quality appraisal of the evidence (9), did not assess determinants of non-adherence (12), or had a broad geographical focus with limited representation of SSA (8, 13).

Given the high burden of hypertension, low rates of BP control in SSA, and the existing evidence gaps, this systematic review and meta-analysis sought to answer the following questions: 1) What is the contemporary burden of non-adherence to BP-lowering medication among people with hypertension in SSA, and has it changed over time? and 2) What are the determinants of (non-)adherence to BP-lowering medication in SSA?

## Methods

#### Search strategy and selection criteria

The review protocol is registered in the PROSPERO database (CRD42017079838) and published (14). This review was reported according to the Preferred Reporting Items for Systematic reviews and Metaanalysis (PRISMA 2020) guidelines (15). We searched MEDLINE via Ovid, SCOPUS, Web of Science, African Journals Online (AJOL) databases and grey literature through Google Scholar to identify all relevant articles from the inception of databases until 6 December 2023. Search terms related to BPlowering medication and adherence were combined with relevant Boolean operators and a validated African search filter (16) to improve the sensitivity and precision of the search. No language restrictions were applied. See **Tables S1-S4** for the detailed search strategies.

We included primary observational studies reporting the prevalence of or factors associated with (non-) adherence to BP-lowering medication among adults with hypertension residing in SSA. We excluded studies conducted out of SSA, studies that selected participants based on their medication adherence status, and those with incomplete data or lacking relevant data to compute the prevalence of non-adherence. We excluded studies with less than 30 participants, letters to the editor, commentaries, reports without primary data, or explicit descriptions of the methods. Duplicate studies based on the same data were excluded and only the most comprehensive report was retained.

#### Screening and data extraction

Following the database search, we uploaded all records to the Rayyan systematic review software (17) and removed all duplicates. Two investigators (LNA and FNT) independently screened titles and abstracts. Full texts of potentially eligible studies were assessed for final inclusion (LNA and VNA), and data was independently extracted by two reviewers (LNA, VNA, FNT, MAN, CAN, and CN). We resolved any disagreements by consensus discussion. The following data were extracted from individual studies: the last name of the first author and year of publication, year(s) of recruitment, the country, study design, study setting (rural vs urban) and study type (community-based vs. hospital-based), method or tool used to define medication adherence, approach to data collection (interview-administered vs. self-administered), sample size, total number of patients non-adherent to BP-lowering medication, mean or median age, and the male proportion. For multinational studies, we extracted the combined data first and, where possible, the disaggregated (country-specific) data. For studies reporting on factors associated with medication adherence, we extracted measures of association and confidence intervals for variables based on multivariable regression analyses.

#### **Risk of bias assessment**

We used the risk of bias tool developed by Hoy *et al.* (18) to evaluate the methodological quality of prevalence studies. The tool assesses selection/sampling methods, response rate, outcome measurement and validity of reporting. We used the Newcastle-Ottawa Scale (NOS) to assess cohort studies (19), which includes eight items spread across three domains: selection of participants, comparability, and outcome assessment. Two reviewers (LNA and CAN) independently assessed the quality of studies and any disagreements resolved by consensus.

#### **Data analysis**

A random effects meta-analysis using the DerSimonian-Laird method was used to estimate the pooled prevalence of non-adherence to BP-lowering medication. We used the Freeman-Tukey double arcsine transformation to stabilize the variance before meta-analysis (20). We assessed between-study heterogeneity using Cochran's Q test and the I<sup>2</sup> statistic. I<sup>2</sup> values < 30%, 30–49%, 50–74% and  $\geq$ 75% represented low, moderate, substantial, and considerable variation in study-specific estimates due to heterogeneity (21). We performed multiple subgroup analyses to investigate potential sources of heterogeneity. The Q test based on the analysis of variance was used to compare between subgroups. For studies reporting high, medium, and low adherence levels, as opposed to adherent vs. nonadherent, we defined non-adherence as having low adherence as non-adherent. Additionally, we estimated the prevalence of non-adherence using only studies with low risk of bias. We conducted an influence analysis to investigate the impact of individual studies on the pooled estimate.

To examine for small study effects, we used the Doi plot and the Luis-Furuya Kanamori (LFK) index. Compared to the traditional funnel plot and Egger's regression test, these measures have been shown to have better visual representation of asymmetry and diagnostic accuracy in detecting small study effects. An LFK index of zero represents complete symmetry in the Doi plot, while any values beyond  $\pm 1$  are consistent with plot asymmetry (22, 23). All statistical analyses were conducted in R Studio (R version 4.2.3) using the 'meta' and 'metasens' packages.

## Results

#### **Overview** of included studies

The search identified 1,315 records. After removing duplicates and screening titles and abstracts, we assessed 158 full texts for eligibility. We included 95 studies comprising 34,102 adults with hypertension in the systematic review and meta-analysis (**Figure 1**). There were two multi-country studies, one with twelve countries (24) and the other with two countries (25). Overall, most of the studies were conducted in Western SSA countries (n = 50, 47.2%), including Nigeria (n = 29), Ghana (n = 11), Côte d'Ivoire (n = 4), Togo (n = 2), and Benin, Guinea, Mauritania, Senegal with one study each. The second most represented region was Eastern SSA (n = 34, 32.1%), including Ethiopia (n = 23), Kenya (n = 3), Eritrea and Tanzania with 2 studies each, and Malawi, Mozambique, Seychelles, and Uganda with one study each. Next was Southern SSA (n = 13, 12.3%), with studies conducted in South Africa (n = 5), Zimbabwe (n = 3), Namibia (n = 2) and one each in Botswana, Lesotho, and Zambia. Finally, studies from Central SSA (n = 9, 8.5%) included Cameroon (n = 4), the Democratic Republic of Congo (n = 2), Congo (n = 2) and one in Gabon.

The most frequently used tool to measure adherence was the eight-item Morisky Medication Adherence Scale (MMAS-8) (n = 25, 26.3%) (24-48). In 21 studies (22.1%), the authors used the proportion of days medication was taken (PDMT  $\geq$  80%) per week (49-69). The next most frequently used tool was the Hill-Bone Compliance Questionnaire (n = 11, 11.6%) (70-80). The pill count method was used in six studies (6.3%) (81-86), and only one study used biological assays (87). Most studies were cross-sectional (n = 89, 93.7%), whereas six were cohort studies (6.3%). Forty-eight (50.5%) studies were conducted in urban settings, five (5.3%) in rural, and forty-two (44.2%) in both urban and rural settings. Almost all the included studies were hospital-based (93.7%). About three-quarters (n = 67, 70.5%) of studies were rated as having a low risk of bias, whereas the remaining studies (n = 28, 29.5%) had a moderate risk of bias. (**Table 1** and **Tables S5-S7**).

#### Burden of non-adherence to BP-lowering medication

#### Overall

The prevalence of non-adherence to BP-lowering medication from individual studies ranged from 3.5% (26) to 92.9% (69). The pooled prevalence of non-adherence across all studies was 43.5% (95% CI: 39.4 – 47.6), with substantial between-study heterogeneity ( $I^2 = 98.3\%$ , p < 0.0001) (**Figure 2**). Metaregression analysis showed no change in the prevalence of non-adherence over time (coefficient: -0.004, 95% CI: -0.011 to 0.004), (**Figures S1 and S2**). In sensitivity analysis, the prevalence of non-adherence was similar to the main analysis estimate when considering only studies with low risk of bias (**Figure** 

**S3**). However, classifying people in the medium adherence category (n=19 studies) as being non-adherent to their medication resulted in a higher overall prevalence of non-adherence (51.3%, 95%CI: 46.1 – 56.6;  $I^2 = 99\%$ ) (**Figure S4**).

### Sub-group analysis

The burden of non-adherence to BP-lowering medication varied by age (p = 0.014), with younger participants (< median age 57 years) having greater non-adherence (47.9%;  $I^2 = 97.6\%$ ) compared to older participants ( $\geq$  57 years) (38.8%;  $I^2 = 97.6\%$ ) (**Table 1** and **Figure S5**). Non-adherence also varied by measurement tool (p = 0.028). The prevalence of non-adherence was 39.8% (25 studies,  $I^2 = 98.5\%$ ) for the most frequently used tool (MMAS-8), lowest (29.7%) among studies using other questionnaires (7 studies,  $I^2 = 98.0\%$ ) and highest (61.9%) in studies using the Medication Adherence Rating Scale (4 studies,  $I^2 = 94.1\%$ ) (**Table 1** and **Figure S6**). There was no sex difference in non-adherence to BPlowering medication (47.4%, 43 studies with 9,903 women vs. 48.2%, 44 studies with 16,733 men, p =0.855). There was no statistical difference in the prevalence of non-adherence between Southern SSA (35.4%, 13 studies,  $I^2 = 98.2\%$ ) compared to Western SSA (42.1%, 50 studies,  $I^2 = 98.5\%$ ), Central SSA (43.2%, 9 studies,  $I^2 = 95.2\%$ ) and Eastern SSA (43.6%, 34 studies,  $I^2 = 97.4\%$ ) (p = 0.613). Similarly, the prevalence of non-adherence did not differ by location (49.7% for rural vs. 43.5% for urban; p =0.233), study settings, study design, sample size, sampling method, period of data collection or data collection approach (**Table 1** and **Figures S7–S16**).

#### Influence analysis and publication bias

The influence analysis found no evidence that any individual study-specific estimate significantly influenced the pooled estimate (*Figure S17*). Additionally, we found no evidence of small study effects as the Doi plot was visually symmetrical, and confirmed with the LFK statistic (LFK index = 0.56) (Figure S18).

#### Factors associated with medication non-adherence

Figure 3 and Table S8 present the details of the predictors of medication non-adherence, which are summarised below.

#### Demographic and socioeconomic factors

Age, sex, and area: All but one (69) of six studies found that being male was associated with nonadherence to medication (88-92). Additionally, three out of five studies showed younger adults (generally < 40 years) were more likely to be non-adherent to medication compared to older adults (48, 84, 93), but

two studies found the contrary (89, 94). One study reported that residing in rural areas was associated with non-adherence (94).

Education: All five studies showed that lower levels of education were associated with non-adherence to medication (41, 67, 82, 86, 95).

Employment and income: Being unemployed was associated with poor medication adherence in four studies (32, 71, 90-92), whereas three authors found the opposite relationship (32, 43, 67). Additionally, three (24, 67, 76) out of five studies reported that higher income/wealth status was associated with good medication adherence, whereas the converse was found in two studies (71, 93).

Social support: All but one (71) of four studies (32, 41, 71, 75) noted that having good family/friend support was associated with good medication adherence, with odds ratios ranging from two (32) to over five-fold (75).

Distance from health facility: Two studies showed that people experiencing high cost or lack of transport had over three times the odds of being non-adherent to medication (72, 92); individuals with shorter distances to the hospital had a two-fold higher odds of being adherent (aOR: 2.02, 1.19 to 3.43) (88).

Medication cost and availability: Unavailability of medication was associated with non-adherence to medication (71, 81, 95, 96), with the odds ranging from 1.7 (95%CI: 1.1 to 3.3) in a study in Tanzania (81) to 5.4 (95%CI: 1.76 to 16.85) in Namibia (71). All seven studies investigating cost coverage for medication found that compared to having free medication or funded by others/insurance/government schemes, self-funded or out-of-pocket costs were associated with non-adherence to medication (34, 36, 41, 46, 48, 81, 95).

#### Patient-related factors

Active participation in management: All eight studies found that patients who actively participated in the management of their BP through regular attendance to clinic appointments (71, 75, 91), health talks (92), having good self-efficacy (82, 90) and not stopping medication when asymptomatic (70, 81) were more likely to have good medication adherence.

Understanding and perceptions about hypertension: Patients with a good understanding of hypertension were three to nine times as likely to be adherent to their medication compared to those who had a poor understanding of the condition (27, 34, 45, 88-90, 92).

Knowledge and skill in managing symptoms and treatment: Patients with adequate knowledge and skill had 3 to 13-fold higher odds of being adherent to medication compared to their counterparts (30, 37, 70, 87, 88, 94, 95, 97).

Perception of the health risk related to hypertension: All but one (27) of four studies found that people with accurate perceptions had higher odds of being adherent to their medication (32, 96, 97).

Comorbidities: In six studies, patients with one or more comorbidities were over twice as likely to be non-adherent to their medication (36, 43, 61, 84, 88, 95). One study reported that those without a comorbid condition were about four times as likely to be adherent to their medication (34).

Alcohol use and smoking: All studies evaluating the impact of alcohol use (27, 36, 37, 70) and smoking (61, 70) found that both behaviours were associated with low or non-adherence to medication.

Stress and forgetfulness: Patients who reported being stressed were twice as likely to be non-adherent to medication, whereas being forgetful was associated with about 8-fold higher odds of non-adherence to medication (45, 46).

Others: Persons using non-prescribed medication (96) or traditional medications (24) were twice as likely to be non-adherent to their BP-lowering medication. Similarly, being physical inactive (aOR: 1.63, 1.04 to 2.55) was associated with non-adherence to medication (43).

#### Therapy-related factors

Pill burden: Eight studies reported that high pill burden was associated with non-adherence to medication (36, 46, 84, 86, 89, 93, 94, 98), with poorer adherence in people taking two or more BP-lowering pills (36, 46, 89, 94).

Side-effects: All six studies showed that those who experienced side effects (such as dizziness (72), palpitation (70)) were two to seven times more likely to be non-adherent to their medication (37, 46, 70, 72, 82, 96).

Duration of diagnosis and treatment: Three studies showed that people who had been diagnosed or on treatment for longer than one (37), five (98) or ten years (93) were more likely to be non-adherent, while two studies showed that being on treatment for three or more years was associated with good medication adherence (34, 76).

BP control and class of BP-lowering medication: All three studies exploring the relation with BP control found that people with well-controlled BPs were two to three times more likely to be adherent to their medication (61, 88, 96). Two studies found a significant relationship between the use of calcium-channel blockers and medication adherence, although both had differing conclusions (24, 37).

#### Healthcare team/health system factors

Good patient-doctor relationships: This was associated with up to four-fold higher odds of adherence (34), whereas a poor relationship was associated with non-adherence to medication (95).

Health education: Two studies showed that patients who did not receive health education or counselling when attending health facilities were twice as likely to be non-adherent to their medication (41, 96).

## Discussion

This systematic review provides a comprehensive synthesis of the burden of non-adherence to BPlowering medication among adults with hypertension in SSA. At least two out of every five adults on treatment for hypertension in SSA were non-adherent to their medication. Non-adherence was higher in younger (mean age < 57 years) adults compared to older adults, and it varied by measurement method. Socioeconomic- and patient-related factors were the most frequently reported drivers of medication adherence in SSA. There was consistent evidence that active patient participation in management, accurate understanding and perceptions, and knowledge of hypertension and its treatment predicted good adherence to medication, while high pill burden (mostly more than two pills per day), medication cost, experiencing side effects, and having comorbidities predicted poor adherence.

The overall prevalence of non-adherence in this study was lower than the 62.5% and 65.9% reported by previous studies in Africa (9, 10). These reviews had very narrow periods for which data was included, ranging from seven to eleven years, as opposed to the present review, which pooled data from studies published over the last three decades. Nevertheless, the estimates of the present study are on par with findings from a global meta-analysis that found a prevalence of non-adherence—measured using questionnaires—of 43% in LMICs, which was higher than the 26% to 38% reported from high-income countries (8).

Non-adherence to BP-lowering medication was higher in studies with younger populations compared to those with older persons, consistent with reports from both LMICs and HICs (8, 13, 99). Older adults are more likely to have chronic conditions and to dedicate more time to their health and therapy. Furthermore, the use of adherence aids like pill boxes and calendars likely enhances their ability to adhere to medication (100). We also found variations in the pooled prevalence of non-adherence by the tool used in assessing medication adherence, consistent with previous reviews (8, 13). There is currently no gold standard for measuring adherence. Thus, the observed variation could reflect differences inherent to the respective tools (101, 102).

Socioeconomic and patient-related factors were the major drivers reported for non-adherence to BPlowering medications. This is consistent with prior systematic reviews (10, 11, 13). However, we found conflicting results for age and employment status. While some studies showed that older age was associated with good adherence, three out of five studies reported an inverse relationship. The latter could be due to declining cognitive ability with ageing. Being employed is correlated with higher socioeconomic status and access to healthcare services, which could explain better adherence (13). In contrast, the association between employment and non-adherence could be due to patients prioritizing their job schedules. These mixed results likely indicate a complex relationship between age, employment, and medication adherence and potential differences in study settings.

Active patient participation and good knowledge of hypertension, and their treatment were the main patient-specific factors consistently associated with good medication adherence. Targeted interventions promoting these attributes should be a key focus in SSA. There is growing evidence elsewhere about the benefits of active patient involvement in decision-making about their health and adherence to therapy (100, 103, 104). These benefits include increased satisfaction, quality of life, and improved understanding of hypertension.

Comorbidities, experiencing medication side effects, and taking multiple pills were associated with medication non-adherence. Similar results were reported among older adults (11). People with multiple chronic conditions are likely to have a high pill burden and incur significant out-of-pocket health expenditures (105, 106). This is a particular challenge for patients in LMICs such as SSA with limited insurance or universal health coverage (107). There is strong evidence that most people with high BP require two medications to control their BP. Hence, simplifying treatments through single-pill combinations (SPC) is likely to address the problem of pill burden and adherence, with spin-offs like improved quality of life, reduced clinical inertia and lower healthcare costs (108-110).

### Implications of the findings.

The population of Africa is projected to increase from 1.4 billion now to ~2.5 billion by 2050, representing the fastest population growth worldwide (111). Our analysis shows the prevalence of non-adherence to BP-lowering medication has not changed over time. With one in three adults having hypertension (4), health systems in SSA can expect to manage ~825 million people with hypertension. Assuming this pattern continues, this would approximate to over 350 million patients not adherent to their medication, and at increased risk of cardiovascular events. This represents a substantial challenge for already struggling health systems. Hence, in addition to prioritising primordial prevention, governments in SSA need to develop sustainable longterm strategies. For example, accelerating progress towards universal health coverage for the delivery of quality and equitable healthcare for all, and fostering teambased care to improve healthcare provider-patient ratios and relationships (112). Furthermore, with SPCs now on the WHO Essential Medicines List (113), stakeholders involved in BP control should adopt simple and practical treatment guidelines incorporating SPCs. Additionally, governments need to facilitate supply chains that enhance the availability of these SPCs for patients. Such strategies would contribute to improving adherence to therapy, BP control and CVD outcomes.

#### Strengths and limitations

The review had some limitations. First, most of the included studies were hospital-based. Hence, the estimate of medication non-adherence may be biased by the 'white coat adherence' phenomenon,

whereby patients are more adherent in the days leading up to and immediately after their clinic visit (114, 115). Consequently, the prevalence presented in this study may be an underestimation of the true prevalence of medication non-adherence in SSA. Second, over half of the included studies were from western SSA, with lower representations from central and southern SSA. Furthermore, there were comparatively fewer studies conducted in rural areas. Hence, the estimate from this review might not be generalizable to the whole of SSA. Third, there was substantial heterogeneity between the studies, which was not completely explained by the variables in the sub-group analyses. Furthermore, the prevalence of non-adherence varied based on the adherence measurement method. More research is needed to develop standardized cost-effective and pragmatic tools for assessing medication adherence for research and clinical practice in SSA. Despite these shortcomings, this systematic review provides a comprehensive synthesis of the evidence from mostly high-quality studies on the burden and determinants of non-adherence to BP-lowering medication in SSA.

## Conclusions

This systematic review showed a substantially high burden of non-adherence to BP-lowering medication among adults with hypertension in SSA; two out of every five adults treated for hypertension are not adherent to their therapy, and this has not changed over the last three decades. Targeted policies are needed to address the broad range of socioeconomic, health system, therapy, and patient-related factors driving this high burden of medication non-adherence in SSA.

#### Funding: None.

Competing interests: None.

**Data availability:** All data underpinning this review are provided in the main manuscript and supplementary files.

#### Identification of new studies via databases and registers

Identification of new studies via other methods




Figure 1: PRISMA flow diagram depicting the selection of studies for inclusion in the review.

Grouping variable	Subgroup	Number (%) of studies	Number of observations	Prevalence % (95% CI)	Tau <sup>2</sup>	I <sup>2</sup> , %	P-value for heterogeneity	P-value for subgroup differences
Overall	-	95 (100)	34,102	43.5 (39.4 to 47.6)	0.041	98.3	< 0.001	-
African regions	Central SSA	9 (8.5)	2,354	43.2 (34.1 to 52.5)	0.019	95.2	< 0.01	0.625
C C	Eastern SSA	34 (32.1)	11,835	43.6 (38.0 to 49.2)	0.027	97.4	< 0.01	-
	Southern SSA	13 (12.3)	4,427	35.4 (25.1 to 46.4)	0.041	98.2	< 0.01	_
	Western SSA	50 (47.2)	15,486	42.1 (35.8 to 48.6)	0.052	98.5	< 0.001	_
Adherence	MMAS-8	25 (26.3)	11,020	39.8 (32.4 to 47.6)	0.038	98.5	< 0.01	0.028
measurement*	Hill-Bone Comp. Q	11 (11.6)	3,281	47.9 (33.8 to 62.3)	0.059	98.6	< 0.01	-
	MMAS-4	10 (10.5)	3,131	45.9 (37.8 to 54.3)	0.017	95.4	< 0.01	-
	MGL scale	6 (6.3)	2,111	44.1 (19.1 to 70.8)	0.115	99.4	< 0.01	_
	Pill count	6 (6.3)	2,438	47.7 (28.3 to 67.4)	0.061	98.9	< 0.01	_
	Girerd scale	5 (5.3)	1,896	48.3 (38.4 to 58.4)	0.012	93.8	< 0.01	_
	MARS	4 (4.2)	1,551	61.9 (51.8 to 71.7)	0.010	94.1	< 0.01	_
	Other Questionnaires	6 (6.3)	1,887	29.1 (15.6 to 44.7)	0.040	98.0	< 0.01	_
	PDMT and related	21 (22.1)	6,600	42.7 (35.3 to 50.2)	0.030	97.4	<0.01	_
Risk of bias	Low risk	67 (70.5)	25,735	42.9 (37.9 to 48.0)	0.044	98.5	< 0.01	0.577
	Moderate risk	28 (29.5)	8,367	44.8 (38.0 to 51.8)	0.034	97.5	< 0.01	_
Median age (57 years)	At or above	41 (49.4)	16,818	38.8 (33.8 to 43.9)	0.028	97.6	< 0.001	0.015
	Below	42 (50.6)	13,297	47.9 (42.8 to 53.2)	0.029	97.6	< 0.001	_
Sex	Female	43 (49.4)	9,903	47.4 (40.8 to 53.9)	0.046	97.7	< 0.001	0.863
	Male	44 (50.6)	16,733	48.2 (42.1 to 54.2)	0.039	95.9	< 0.01	_
Median sample size	At or above	50 (52.6)	25,546	43.4 (37.8 to 49.2)	0.043	98.9	< 0.001	0.966
(329 persons)	Below	45 (47.4)	8,556	43.6 (37.9 to 49.4)	0.038	96.6	< 0.01	_
Study location	Urban	58 (79.5)	18,890	43.5 (37.5 to 49.6)	0.055	98.6	< 0.001	0.222
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Rural	15 (20.5)	3,169	49.7 (41.7 to 57.7)	0.023	95.0	< 0.01	_
Study setting	Hospital	89 (93.6)	32,691	43.4 (39.2 to 47.7)	0.042	98.4	< 0.001	0.792
	Community	6 (6.3)	1,411	45.2 (32.5 to 58.3)	0.025	95.7	<0.01	_
Study design	Cross-sectional	89 (93.6)	31,138	43.4 (39.3 to 47.6)	0.039	98.2	< 0.001	0.901
	Cohort	6 (6.3)	2,964	44.8 (24.1 to 66.5)	0.074	99.2	< 0.01	
Period of data	Before 2010	13 (13.7)	4,059	49.3 (35.5 to 63.1)	0.064	98.7	< 0.01	0.839
collection	2010 to 2014	20 (21.1)	5,935	44.6 (37.5 to 51.9)	0.026	96.7	< 0.01	_
	2015 to 2019	38 (40.0)	15,607	42.9 (35.9 to 49.9)	0.048	98.7	< 0.001	_
	2020 onward	17 (17.9)	6,610	39.9 (30.9 to 49.3)	0.038	98.3	<0.01	_
	Not reported	7 (7.4)	1,891	42.2 (33.0 to 51.7)	0.015	94.1	<0.01	_
Sampling method	Probabilistic	35 (36.8)	12,034	40.9 (34.8 to 47.2)	0.035	97.9	<0.001	0.509
Sumpring method	Non-probabilistic	55 (57.9)	20,793	44.5 (38.9 to 50.1)	0.044	98.5	<0.001	
	Unclear	5 (5.3)	1,275	51.1 (32.0 to 69.9)	0.048	97.9	<0.01	_
Data collection	Interviewer-administered	89 (93.6)	29,983	43.1 (38.8 to 47.4)	0.043	98.3	<0.001	0.393
2 and concentration	Self-administered	6 (6.3)	4,119	50.4 (34.4 to 66.4)	0.040	98.9	<0.01	,

## Table 1: Sub-group analysis exploring differences in prevalence of non-adherence to BP-lowering medication in Sub-Saharan Africa.

SSA, Sub-Saharan Africa; MMAS-8, Eight-item Morisky Medication Adherence Scale; MMAS-4, Four-item Morisky Medication Adherence Scale; MGL, Morisky-Green-Levine; MARS, Medication Adherence Rating Scale; PDMT, Proportion of days per week medication was taken; Other Questionnaires included the Medication Adherence Questionnaire (MAQ, 1 study), the Brief Medication Questionnaire (BMQ, 1 study), the Adherence to Refills and Medication Scale (ARMS-7, 2 studies), the Adherence in Chronic Disease Scale (ACDS, 1 study), and the General Medication Adherence Scale (GMAS, 1 study).

	Medication cost coverage	▼	▼	▼	▼	▼	▼	▼	
	Female gender						▼		-
	High income					▼	▼		
Socioeconomic-related	High educational status					▼			
factors	Employment				▼	▼			
	Older age			▼	▼	▼			
	Presence of social support				▼				
	Unavilability of medication	▼	▼	▼	▼				
	Short distance & low transport cost to hospital								-
	Participation in management								<b>A</b>
	Knowledge/skill in managing disease and treatment								
	Understanding & perceptions of hypertension								
	Presence of comorbidities	▼	▼	▼	▼	▼	▼	▼	
Patient-related factors	Accurate perception of hypertension health risk				▼				
	Alcohol use	▼	▼	▼	▼				
	Smoking	▼	▼						
	Use of non-prescribed or traditional meds	▼	▼						
	Forgetfulness	▼	▼						
	Stress	▼							-
	Number of pills	▼	▼	▼	▼	▼	▼	▼	▼
Therapy-related factors	Medication side-effects		▼	▼	▼	▼	▼		
	Duration of treatment			▼	▼	▼			
	Having controlled BP								
	Using C-C blocker		▼						
Healthcare team/ health	Good patient-physician relationship								
system-related factors	Absent/ inadequate patient education	▼	▼						

## Figure 3: Factors associated with medication (non-)adherence in sub-Saharan Africa classified according to the World Health Organization dimensions for adherence to medication in people with hypertension.

Note: The upward arrows in green boxes indicate the variable was associated with good medication adherence, while the downward arrows in pink boxes indicate an association with non-adherence. The number of boxes along each variable indicate the number of studies that reported a significant association between that variable and adherence to BP-lowering medication.

## References

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80.

2. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223-49.

3. Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785-802.

4. Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP. Burden of undiagnosed hypertension in sub-saharan Africa: a systematic review and meta-analysis. Hypertension. 2015;65(2):291-8.

5. Kaze AD, Schutte AE, Erqou S, Kengne AP, Echouffo-Tcheugui JB. Prevalence of hypertension in older people in Africa: a systematic review and meta-analysis. J Hypertens. 2017;35(7):1345-52.

6. Bosu WK, Reilly ST, Aheto JMK, Zucchelli E. Hypertension in older adults in Africa: A systematic review and meta-analysis. PLoS One. 2019;14(4):e0214934.

7. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.

8. Lee EKP, Poon P, Yip BHK, Bo Y, Zhu MT, Yu CP, et al. Global Burden, Regional Differences, Trends, and Health Consequences of Medication Nonadherence for Hypertension During 2010 to 2020: A Meta-Analysis Involving 27 Million Patients. J Am Heart Assoc. 2022;11(17):e026582.

9. Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(4):e5641.

10. Shin J, Konlan KD. Prevalence and determinants of medication adherence among patients taking antihypertensive medications in Africa: A systematic review and meta-analysis 2010-2021. Nurs Open. 2023;10(6):3506-18.

11. Uchmanowicz B, Jankowska EA, Uchmanowicz I, Morisky DE. Self-Reported Medication Adherence Measured With Morisky Medication Adherence Scales and Its Determinants in Hypertensive Patients Aged  $\geq 60$  Years: A Systematic Review and Meta-Analysis. Front Pharmacol. 2019;10:168.

12. Biffi A, Rea F, Iannaccone T, Filippelli A, Mancia G, Corrao G. Sex differences in the adherence of antihypertensive drugs: a systematic review with meta-analyses. BMJ Open. 2020;10(7):e036418.

13. Nielsen J, Shrestha AD, Neupane D, Kallestrup P. Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjects. J Hum Hypertens. 2017;31(1):14-21.

14. Agbor VN, Takah NF, Aminde LN. Prevalence and factors associated with medication adherence among patients with hypertension in sub-Saharan Africa: protocol for a systematic review and meta-analysis. BMJ Open. 2018;8(3):e020715.

15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.

16. Sandy C. Health sciences search filters: geographic filters for Africa. Edmonton, AB.: University of Alberta.; 2017 [

17. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.

18. Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934-9.

19. Wells GS, B; O'Connell, D; Peterson, J; Welch, V; Losos, M; Tugwell, P;. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa,

Canada: The Ottawa Hospital Research Institute; 2013 [cited 2024 21 February]. Available from: https://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp.

20. Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974-8.

21. Higgins JT, J; Chandler, J; Cumpston, M; Li, T; Page, MJ; Welch, VA; (editors),. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane; 2023 [cited 2024 21 February]. Available from: <u>www.training.cochrane.org/handbook</u>.

22. Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018;16(4):195-203.

23. Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers RD, Bown MJ. In meta-analyses of proportion studies, funnel plots were found to be an inaccurate method of assessing publication bias. J Clin Epidemiol. 2014;67(8):897-903.

24. Macquart de Terline D, Kane A, Kramoh KE, Ali Toure I, Mipinda JB, Diop IB, et al. Factors associated with poor adherence to medication among hypertensive patients in twelve low and middle income Sub-Saharan countries. PLoS One. 2019;14(7):e0219266.

25. Boima V, Ademola AD, Odusola AO, Agyekum F, Nwafor CE, Cole H, et al. Factors Associated with Medication Nonadherence among Hypertensives in Ghana and Nigeria. Int J Hypertens. 2015;2015:205716.

26. Okunrinboye HI, Otakpor AN, Ilesanmi OS. Depression and medication-adherence in patients with hypertension attending a tertiary health facility in South-West Nigeria. Pan Afr Med J. 2019;33:27.

27. Sarkodie E, Afriyie DK, Hutton-Nyameaye A, Amponsah SK. Adherence to drug therapy among hypertensive patients attending two district hospitals in Ghana. Afr Health Sci. 2020;20(3):1355-67.

28. Gala P, Moshokgo V, Seth B, Ramasuana K, Kazadi E, M'Buse R, et al. Medication Errors and Blood Pressure Control Among Patients Managed for Hypertension in Public Ambulatory Care Clinics in Botswana. J Am Heart Assoc. 2020;9(2):e013766.

29. Akintunde AA, Akintunde TS. Antihypertensive Medications Adherence Among Nigerian Hypertensive Subjects in a Specialist Clinic Compared to a General Outpatient Clinic. Ann Med Health Sci Res. 2015;5(3):173-8.

30. Adeoye AM, Adebiyi AO, Adebayo OM, Owolabi MO. Medication adherence and 24-h blood pressure in apparently uncontrolled hypertensive Nigerian patients. Niger Postgrad Med J. 2019;26(1):18-24.

31. Labaran KM, S; Maiha, BB; Giwa, A; Maaji, HU; Yusuf, H; Ibrahim, AW;. Validity evidence of adapted Hausa version of 8-item Morisky Medication adherence scale in patients with hypertension in North-western Nigeria. Bayero J P Appl Sci. 2018;11(1):244-50.

32. D GT, Berhane Y, Worku A. Adherence to Antihypertensive Treatment and Associated Factors in Central Ethiopia. Int J Hypertens. 2020;2020:9540810.

33. Olowe OA, Ross AJ. Knowledge, adherence and control among patients with hypertension attending a peri-urban primary health care clinic, KwaZulu-Natal. Afr J Prim Health Care Fam Med. 2017;9(1):e1-e7.

34. Mekonnen HS, Gebrie MH, Eyasu KH, Gelagay AA. Drug adherence for antihypertensive medications and its determinants among adult hypertensive patients attending in chronic clinics of referral hospitals in Northwest Ethiopia. BMC Pharmacol Toxicol. 2017;18(1):27.

35. Amadi CA, OA; Joda, AE; Mbakwem, AC; Ajuluchukwu, JN;. Self reported adherence to Antihypertensive drugs in a Nigerian population using the Morisky Medication Adherence Scale. Nig Qt J Hosp Med. 2014;24(2):144-9.

36. Asgedom SW, Atey TM, Desse TA. Antihypertensive medication adherence and associated factors among adult hypertensive patients at Jimma University Specialized Hospital, southwest Ethiopia. BMC Res Notes. 2018;11(1):27.

37. Berhe DF, Taxis K, Haaijer-Ruskamp FM, Mulugeta A, Mengistu YT, Burgerhof JGM, Mol PGM. Impact of adverse drug events and treatment satisfaction on patient adherence with antihypertensive medication - a study in ambulatory patients. Br J Clin Pharmacol. 2017;83(9):2107-17.

38. Otenyo SM, A;. Factors affecting adherence to antihypertensive medication regimen among hemodialysis patients attending a private hospital in Mombasa, Kenya. Int J Pharm Sci Res. 2018;9(2):755-60.

39. Ibrahim UM, S; Zezi, AU; Lawal, BK;. Adherence to antihypertensive medications in patients attending public hospitals in Kano state, Nigeria. Bayero J P Appl Sci. 2019;12(1):395-400.

40. Jande MK, DM; Sravanam, P; Marwa, C; Madlan, B; Burger, J; Godman, B; Oluka, M; Massele, A; Mwita, S;. Patient-related beliefs and adherence towards their medications among the hypertensive outpatients in Tanzania. J Compar Eff Res. 2017;6(3):185-93.

41. Kebede BM, M;. Antihypertensive medication non-adherence and predictors among adult patients on follow-up, Ethiopia: Prospective cross-sectional study. Eur J Clin Pharm. 2020;22(2):70-9.

42. Akpor OO, FO;. Treatment satisfaction and medication adherence among hypertensive patients in a teaching hospital in Ekiti State, Nigeria. J Integr Nurs. 2022;4(2):59-67.

43. Simegn BK, Chelkeba L, Alamirew BD. Clinicians' prescribing pattern, rate of patients' medication adherence and its determinants among adult hypertensive patients at Jimma University Medical Center: Prospective cohort study. PLoS One. 2021;16(11):e0259421.

44. Kebede B, Chelkeba L, Dessie B. Rate of blood pressure control and its determinants among adult hypertensive patients at Jimma University Medical Center, Ethiopia: Prospective cohort study. SAGE Open Med. 2021;9:20503121211006000.

45. Akoko BM, Fon PN, Ngu RC, Ngu KB. Knowledge of Hypertension and Compliance with Therapy Among Hypertensive Patients in the Bamenda Health District of Cameroon: A Cross-sectional Study. Cardiol Ther. 2017;6(1):53-67.

46. Adidja NM, Agbor VN, Aminde JA, Ngwasiri CA, Ngu KB, Aminde LN. Non-adherence to antihypertensive pharmacotherapy in Buea, Cameroon: a cross-sectional community-based study. BMC Cardiovasc Disord. 2018;18(1):150.

47. Kretchy IA, Owusu-Daaku FT, Danquah SA. Mental health in hypertension: assessing symptoms of anxiety, depression and stress on anti-hypertensive medication adherence. Int J Ment Health Syst. 2014;8:25.

48. Okello S, Nasasira B, Muiru AN, Muyingo A. Validity and Reliability of a Self-Reported Measure of Antihypertensive Medication Adherence in Uganda. PLoS One. 2016;11(7):e0158499.

49. Lunt DW, Edwards PR, Steyn K, Lombard CJ, Fehrsen GS. Hypertension care at a Cape Town community health centre. S Afr Med J. 1998;88(5):544-8.

50. Hoffman RM, Chibwana F, Kahn D, Banda BA, Phiri L, Chimombo M, et al. High Rates of Uncontrolled Blood Pressure in Malawian Adults Living with HIV and Hypertension. Glob Heart. 2021;16(1):81.

51. Omolase CA, O; Omolase, BO; Drug Compliance amongst hypertensives in a Nigerian community. TAF Prev Med Bulletin. 2011;10(2):145-8.

52. Beune E, Nieuwkerk P, Stronks K, Meeks K, Schulze MB, Mockenhaupt FP, et al. Medication non-adherence and blood pressure control among hypertensive migrant and non-migrant populations of sub-Saharan African origin: the RODAM study. J Hum Hypertens. 2019;33(2):131-48.

53. Okeahialam B. Adherence and preference issues in anti-hypertensive therapy: Experience from a Private medical facility in Jos, Nigeria. J Med Tropics. 2011;13(0):11-4.

54. Amira CO, Okubadejo NU. Factors influencing non-compliance with anti-hypertensive drug therapy in Nigerians. Niger Postgrad Med J. 2007;14(4):325-9.

55. Tozivepi SN, Takawira S, Chikaka E, Mundagowa P, Chadambuka EM, Mukora-Mutseyekwa F. The Nexus Between Adherence to Recommended Lifestyle Behaviors and Blood Pressure Control in Hypertensive Patients at Mutare Provincial Hospital, Zimbabwe: A Cross-Sectional Study. Patient Prefer Adherence. 2021;15:1027-37.

56. Fentaw Z, Adamu K, Wedajo S. Blood pressure control status of patients with hypertension on treatment in Dessie City Northeast Ethiopia. BMC Public Health. 2022;22(1):917.

57. Thinyane KH, Mothebe T, Sooro M, Namole LD, Cooper V. An observational study of hypertension treatment and patient outcomes in a primary care setting. Pan Afr Med J. 2015;20:424.

58. Sisay YA, H; Biratu, TD; Legesse, TG;. Uncontrolled Hypertension and Behavioral Risk Factors among Adult Hypertensive Patients at Saint Paul's Hospital, Millennium Medical College, Addis Ababa, Ethiopia. Advances in Public Health. 2022;2022:Article ID 7518860.

59. Sheleme T, Jilo O, Bekele F, Olika W, Safera B, Babu Y. Uncontrolled blood pressure and contributing factors among patients with hypertension at outpatient care of Bedele General Hospital, Southwest Ethiopia: A cross-sectional study. SAGE Open Med. 2022;10:20503121221126333.

60. Ndege BD, LO; Owiti, MOG; Anjichi, G; Siika, AM;. Prevalence, treatment and control of hypertension among type-2 diabetic patients at Moi Teaching and referral hospital, Eldoret, Kenya. East Afr Med J. 2014;91(8):253-60.

61. Rampamba EM, Meyer JC, Godman B, Kurdi A, Helberg E. Evaluation of antihypertensive adherence and its determinants at primary healthcare facilities in rural South Africa. J Comp Eff Res. 2018;7(7):661-72.

62. Kabir MI, Z; Abubakar, IS; Jibril, M;. Compliance to medication among hypertensive patients in Murtala Mohammed Specialist Hospital, Kano, Nigeria. J Comm Med Prim Health Care. 2004;16(1):16-20.

63. Chika AU, EU; Oricha, SB; Isezuo, SA;. Gender disparity in antihypertensive utilization and blood pressure control. Sahel Med J. 2009;12(4):155-8.

64. Osamor PE, Owumi BE. Factors associated with treatment compliance in hypertension in southwest Nigeria. J Health Popul Nutr. 2011;29(6):619-28.

65. Tebelu DT, Tadesse TA, Getahun MS, Negussie YM, Gurara AM. Hypertension self-care practice and its associated factors in Bale Zone, Southeast Ethiopia: A multi-center cross-sectional study. J Pharm Policy Pract. 2023;16(1):20.

66. Iloh GO, JN; Njoku, PU; Amadi, AN; Godswill-Uko, EU;. Medication adherence and blood pressure control amongst adults with primary hypertension attending a tertiary hospital primary care clinic in Eastern Nigeria. Afr J Prm Health Care Fam Med. 2013;5(1):6p.

67. Obirikorang Y, Obirikorang C, Acheampong E, Odame Anto E, Gyamfi D, Philip Segbefia S, et al. Predictors of Noncompliance to Antihypertensive Therapy among Hypertensive Patients Ghana: Application of Health Belief Model. Int J Hypertens. 2018;2018:4701097.

68. Dedefo MG, Gemechu DB, Fekadu G, Tekle Dibessa T. Blood Pressure Control among Hypertensive Diabetic Patients on Follow-Up at Chronic Clinic of Nekemte Referral Hospital in West Ethiopia. Int J Hypertens. 2020;2020:7526257.

69. Ohene Buabeng K, Matowe L, Plange-Rhule J. Unaffordable drug prices: the major cause of noncompliance with hypertension medication in Ghana. J Pharm Pharm Sci. 2004;7(3):350-2.

70. Woode E, Boakye-Gyasi E, Obirikorang Y, Adu EA, Obirikorang C, Acheampong E, Odame-Anto E. Predictors of medication nonadherence among hypertensive clients in a Ghanaian population: Application of the Hill-Bone and Perceived Barriers to Treatment Compliance Scale. Health Sci Rep. 2022;5(3):e584.

71. Nakwafila O, Mashamba-Thompson T, Godi A, Sartorius B. A Cross-Sectional Study on Hypertension Medication Adherence in a High-Burden Region in Namibia: Exploring Hypertension Interventions and Validation of the Namibia Hill-Bone Compliance Scale. Int J Environ Res Public Health. 2022;19(7).

72. Mweene MB, J; Andrews, B; Mweene, MM; Lakhi, S;. Factors Associated With Poor Medication Adherence In Hypertensive Patients In Lusaka, Zambia. Med J Zambia. 2010;37(3):252-61.

73. Goverwa TP, Masuka N, Tshimanga M, Gombe NT, Takundwa L, Bangure D, Wellington M. Uncontrolled hypertension among hypertensive patients on treatment in Lupane District, Zimbabwe, 2012. BMC Res Notes. 2014;7:703.

74. Solomon M, Negussie YM, Bekele NT, Getahun MS, Gurara AM. Uncontrolled blood pressure and associated factors in adult hypertensive patients undergoing follow-up at public health facility ambulatory clinics in Bishoftu town, Ethiopia: a multi-center study. BMC Cardiovasc Disord. 2023;23(1):258.

75. Nashilongo MM, Singu B, Kalemeera F, Mubita M, Naikaku E, Baker A, et al. Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications. Cardiovasc Drugs Ther. 2017;31(5-6):565-78.

76. Abeasi DA, D; Akumiah, PO;. Predictors of Medication Adherence Among Adults With Hypertension in Ghana. J Client-Cent Nurs Care. 2022;8(1):23-32.

77. Attahiru M, Simon PL, Mutalub YB, Akangoziri MD, Grema BA. Predictors of blood pressure control amongst primary care patients of a teaching hospital in Bauchi, North-Eastern Nigeria. Niger Postgrad Med J. 2023;30(1):46-52.

78. Onwukwe SC, Ngene NC. Blood pressure control in hypertensive patients attending a rural community health centre in Gauteng Province, South Africa: A cross-sectional study. S Afr Fam Pract (2004). 2022;64(1):e1-e9.

79. Fekadu G, Adamu A, Gebre M, Gamachu B, Bekele F, Abadiga M, et al. Magnitude and Determinants of Uncontrolled Blood Pressure Among Adult Hypertensive Patients on Follow-Up at Nekemte Referral Hospital, Western Ethiopia. Integr Blood Press Control. 2020;13:49-61.

80. Achieng LJ, MD; Ogola, EN; Karari, E;. Adequacy of Blood Pressure Control and Level of Adherence with Antihypertensive Therapy. East Afr Med J. 2009;86(11):499-506.

81. Pallangyo P, Komba M, Mkojera ZS, Kisenge PR, Bhalia S, Mayala H, et al. Medication Adherence and Blood Pressure Control Among Hypertensive Outpatients Attending a Tertiary Cardiovascular Hospital in Tanzania: A Cross-Sectional Study. Integr Blood Press Control. 2022;15:97-112.

82. Ikechukwu EO, UP; Ogochukwu, AM;. Predictors of self-reported adherence to antihypertensive medication in a Nigerian population. J Basic Clin Pharm. 2010;01(02):133-7.

83. Olowookere AO, SA; Talabi, AO; Etonyeaku, AC; Adeleke, OE; Akinboboye, OO;. Perceived family support and factors influencing medication adherence among hypertensive patients attending a Nigerian tertiary hospital. Ann Trop Med Pub Health. 2015;8(6):241-5.

84. Odiase FO, JE;. Predictors of nonadherence to antihypertensive medications among stroke survivors in Benin City Nigeria. Sub-Saharan Afr J Med. 2019;6:122-8.

85. Busari OO, T; Olufemi, O; Desalu, O; Opadijo, OG; Jimoh, AK; Agboola, SM; Busari, OE; Olalekan, O;. Impact of patients knowledge, attitude and practices on hypertension on compliance with antihypertensive drugs in a resource-poor setting. TAF Prev Med Bulletin. 2010;9(2):87-92.

86. Josephs V. Compliance of Nigerians with drug treatment os systemic hypertension: is this just a literacy problem. J Med Biomed Res. 2013;12(1):8p.

87. Hungerbuhler P, Bovet P, Shamlaye C, Burnand B, Waeber B. Compliance with medication among outpatients with uncontrolled hypertension in the Seychelles. Bull World Health Organ. 1995;73(4):437-42.

88. Ambaw AD, Alemie GA, SM WY, Mengesha ZB. Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC Public Health. 2012;12:282.

89. Tibebu A, Mengistu D, Bulto LN. Adherence to prescribed antihypertensive medications and associated factors for hypertensive patients attending chronic follow-up units of selected public hospitals in Addis Ababa, Ethiopia. Int J Health Sci (Qassim). 2017;11(4):47-52.

90. Andualem A, Liknaw T, Edmealem A, Gedefaw M. Adherence to antihypertensive medications among adult hypertensive patients attending chronic follow-up units of Dessie Referral Hospital, Northeastern Ethiopia: A cross-sectional study. Medicine (Baltimore). 2021;100(31):e26818.

91. Bamidele ES, K; Adefala, N; Osinaike, A; Omotosho, A;. Drug adherence among adult hypertensives attending medical out-patient clinic in a tertiary hospital in Ogun State, Nigeria. Babcock Uni Med J. 2020;3(1):37-44.

92. Mebrahtu G, M MM, Okoth Achila O, Seyoum Y, Adnoy ET, Ovberedjo M. Antihypertensive Medication Adherence and Associated Factors: A Cross-Sectional Analysis of Patients Attending a National Referral Hospital in Asmara, Eritrea. Patient Prefer Adherence. 2021;15:2619-32.

93. Kretchy IA, Boima V, Agyabeng K, Koduah A, Appiah B. Psycho-behavioural factors associated with medication adherence among male out-patients with hypertension in a Ghanaian hospital. PLoS One. 2020;15(1):e0227874.

94. Teshome DF, Bekele KB, Habitu YA, Gelagay AA. Medication adherence and its associated factors among hypertensive patients attending the Debre Tabor General Hospital, northwest Ethiopia. Integr Blood Press Control. 2017;10:1-7.

95. Abdisa L, Alemu A, Heluf H, Sertsu A, Dessie Y, Negash B, et al. Factors associated with poor medication adherence during COVID-19 pandemic among hypertensive patients visiting public hospitals in Eastern Ethiopia: a cross-sectional study. BMJ Open. 2022;12(10):e064284.

96. Lulebo AM, Mutombo PB, Mapatano MA, Mafuta EM, Kayembe PK, Ntumba LT, et al. Predictors of non-adherence to antihypertensive medication in Kinshasa, Democratic Republic of Congo: a cross-sectional study. BMC Res Notes. 2015;8:526.

97. Ikama MS, Nsitou BM, Loumouamou M, Kimbally-Kaky G, Nkoua JL. [Drug compliance and its factors in a group of hypertensive Congolese]. Pan Afr Med J. 2013;15:121.

98. Baah-Nyarkoh E, Alhassan Y, Dwomoh AK, Kretchy IA. Medicated-related burden and adherence in patients with co-morbid type 2 diabetes mellitus and hypertension. Heliyon. 2023;9(4):e15448.

99. Chang TE, Ritchey MD, Park S, Chang A, Odom EC, Durthaler J, et al. National Rates of Nonadherence to Antihypertensive Medications Among Insured Adults With Hypertension, 2015. Hypertension. 2019;74(6):1324-32.

100. Náfrádi L, Galimberti E, Nakamoto K, Schulz PJ. Intentional and Unintentional Medication Non-Adherence in Hypertension: The Role of Health Literacy, Empowerment and Medication Beliefs. J Public Health Res. 2016;5(3):762.

101. Kwan YH, Weng SD, Loh DHF, Phang JK, Oo LJY, Blalock DV, et al. Measurement Properties of Existing Patient-Reported Outcome Measures on Medication Adherence: Systematic Review. J Med Internet Res. 2020;22(10):e19179.

102. Lam WY, Fresco P. Medication Adherence Measures: An Overview. Biomed Res Int. 2015;2015:217047.

103. Kvarnström K, Westerholm A, Airaksinen M, Liira H. Factors Contributing to Medication Adherence in Patients with a Chronic Condition: A Scoping Review of Qualitative Research. Pharmaceutics. 2021;13(7).

104. Lambert-Kerzner A, Havranek EP, Plomondon ME, Fagan KM, McCreight MS, Fehling KB, et al. Perspectives of patients on factors relating to adherence to post-acute coronary syndrome medical regimens. Patient Prefer Adherence. 2015;9:1053-9.

105. Allaham KK, Feyasa MB, Govender RD, Musa AMA, AlKaabi AJ, ElBarazi I, et al. Medication Adherence Among Patients with Multimorbidity in the United Arab Emirates. Patient Prefer Adherence. 2022;16:1187-200.

106. Drzayich Antol D, Waldman Casebeer A, Khoury R, Michael T, Renda A, Hopson S, et al. The relationship between comorbidity medication adherence and health related quality of life among patients with cancer. J Patient Rep Outcomes. 2018;2:29.

107. Odipo E, Jarhyan P, Nzinga J, Prabhakaran D, Aryal A, Clarke-Deelder E, et al. The path to universal health coverage in five African and Asian countries: examining the association between insurance status and health-care use. Lancet Glob Health. 2024;12(1):e123-e33.

108. Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. Hypertension. 2021;77(2):692-705.

109. Weisser B, Predel HG, Gillessen A, Hacke C, Vor dem Esche J, Rippin G, et al. Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering from Hypertension and/or Dyslipidemia: Results of a Meta-Analysis. High Blood Press Cardiovasc Prev. 2020;27(2):157-64.

110. Kengne AP, Brière JB, Le Nouveau P, Kodjamanova P, Atanasov P, Kochoedo M, et al. Impact of single-pill combinations versus free-equivalent combinations on adherence and persistence in patients with hypertension and dyslipidemia: a systematic literature review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2023:1-11.

111. Stanley A. African Century IMF: International Monetary Fund; 2023 [cited 2024 3 May]. Available from: <u>https://www.imf.org/en/Publications/fandd/issues/2023/09/PT-african-century</u>.

112. Dzudie A, Rayner B, Ojji D, Schutte AE, Twagirumukiza M, Damasceno A, et al. Roadmap to achieve 25% hypertension control in Africa by 2025. Cardiovasc J Afr. 2017;28(4):262-72.

113. Benjamin IJ, Kreutz R, Olsen MH, Schutte AE, Lopez-Jaramillo P, Frieden TR, et al. Fixed-dose combination antihypertensive medications. Lancet. 2019;394(10199):637-8.

114. Zueger T, Gloor M, Lehmann V, Melmer A, Kraus M, Feuerriegel S, et al. White coat adherence effect on glucose control in adult individuals with diabetes. Diabetes Res Clin Pract. 2020;168:108392.

115. Poleon S, Sabbagh N, Racette L. Whitecoat Adherence in Patients With Primary Open-Angle Glaucoma. Front Med (Lausanne). 2022;9:867884.

	Events per 100							
Study	Events	Total	observations	Events	95%-CI	Weight		
Okunrinboye 2019	14	400		3.50	[ 1.93; 5.80]	1.1%		
Woode 2022	21	246		8.54	[ 5.36; 12.75]	1.1%		
Sarkodie 2020	39	370	-	10.54	[ 7.60; 14.13]	1.1%		
Sakyi 2023	37	303	-	12.21	[ 8.75; 16.44]	1.1%		
Nakwafila 2022	49	400	-	12.25	[ 9.20; 15.87]	1.1%		
Makukule 2023	55	400	-	13.75	[10.53; 17.52]	1.1%		
Gala 2020	41	280		14.64	[10.72; 19.34]	1.1%		
Lunt 1998	207	1096	-	18.89	[16.61; 21.33]	1.1%		
Hoffman 2021	30	158	_ <b></b> _	18.99	[13.19; 25.98]	1.0%		
Abebe 2023	85	404	-	21.04	[17.17; 25.34]	1.1%		
Omolase 2011	22	100	_ <b></b>	22.00	[14.33; 31.39]	1.0%		
Pallangyo 2022	196	849	-	23.09	[20.29; 26.07]	1.1%		
Akintunde 2015	27	114		23.68	[16.22; 32.56]	1.0%		
Beune 2018	82	333	-	24.62	[20.09; 29.62]	1.1%		
Teshome 2017	84	337		24.93	[20.40; 29.90]	1.1%		
Adeoye 2019	40	148		27.03	[20.06; 34.94]	1.0%		
Kinfe 2020	63	223		28.25	[22.44; 34.65]	1.1%		
Labaran 2018	39	130		30.00	[22.28; 38.66]	1.0%		
lkechukwu 2010	14	47	<u>+</u>	29.79	[17.34; 44.89]	1.0%		
Mweene 2010	71	234		30.34	[24.52; 36.67]	1.1%		
Bamidele 2020	123	404		30.45	[25.99; 35.19]	1.1%		
de Terline 2019	678	2198		30.85	[28.92; 32.82]	1.1%		
Animut 2018	123	395	-	31.14	[26.60; 35.96]	1.1%		
Nurhussein 2018	32	100		32.00	[23.02; 42.08]	1.0%		
Tsadik 2020	319	989	-	32.25	[29.35; 35.27]	1.1%		
Okeahialam 2011	59	182		32.42	[25.68; 39.74]	1.0%		
Olowe 2017	113	348		32.47	[27.58; 37.67]	1.1%		
lkama 2013	69	212		32.55	[26.29; 39.30]	1.0%		
Mekonnen 2017	134	409		32.76	[28.23; 37.55]	1.1%		
Tibebu 2017	134	404		33.17	[28.59; 37.99]	1.1%		
Bioma 2015	121	357		33.89	[28.99; 39.06]	1.1%		
Amira 2007	77	225	- <b></b>	34.22	[28.05; 40.82]	1.1%		
Ambaw 2012	136	384		35.42	[30.63; 40.43]	1.1%		
Tozivepi 2021	126	350		36.00	[30.97; 41.27]	1.1%		
Fentaw 2022	131	360	- <b></b>	36.39	[31.41; 41.59]	1.1%		
Amadi 2014	283	768	-	36.85	[33.43; 40.37]	1.1%		
Thinyane 2015	26	70		37.14	[25.89; 49.52]	1.0%		
Sisay 2022	180	474		37.97	[33.59; 42.51]	1.1%		
Asgedom 2018	108	280		38.57	[32.84; 44.55]	1.1%		
Ayodapo 2020	163	420		38.81	[34.12; 43.65]	1.1%		
Olowookere 2015	164	420		39.05	[34.35; 43.90]	1.1%		
Sheleme 2022	87	219	- <b>B</b>	39.73	[33.20; 46.54]	1.0%		
Menanga 2016	176	440	-	40.00	[35.39; 44.75]	1.1%		
Ndege 2014	74	185		40.00	[32.88; 47.44]	1.0%		
Dego 2016	48	120	— <b>—</b>	40.00	[31.17; 49.34]	1.0%		
Konin 2011	49	121	— <u>—</u>	40.50	[31.67; 49.80]	1.0%		
Adisa 2017	105	250		42.00	[35.81; 48.38]	1.1%		
Kretchy 2020	151	358	- <b>ė</b> -	42.18	[37.01; 47.48]	1.1%		
BemedRxiv preprint doi: (which was not cer	https://dogoorg	/10/2/510 r revie	01/2024.05.28.2430 82; this version pos w) is the author/funder, who has granted i	sted May 2 <b>9</b> 2 <b>20</b> 2 medRxiv a licens	439.be; 4993919 e to display th	ght holder fo		

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit Otenyo 2018 61 It isl #fade available under altC-BY-NC-ND 4.0 International 4i86ns 4.18; 50.87] 1.0% Hungerbuhler 1995 83 187 44.39 [37.14; 51.81] 1.0% Ibrahim 2019 266 598 44.48 [40.45; 48.57] 1.1% Rampamba 2018 45.42 [39.15; 51.80] 114 251 1.1% Kabir 2004 45.83 [40.60; 51.14] 165 1.1% 360 Jande 2017 83 180 46.11 [38.67; 53.68] 1.0% 47.06 [38.95; 55.28]

Kebede 2020	72	153	—			47.06	[38.95; 55.28]	1.0%
Ofoli 2017	57	120	_			47.50	[38.31; 56.82]	1.0%
Andualem 2021	176	366				48.09	[42.87; 53.34]	1.1%
Chika 2009	127	260				48.85	[42.62; 55.10]	1.1%
Adomako 2021	237	485				48.87	[44.33; 53.41]	1.1%
Osamor 2011	217	440				49.32	[44.55; 54.09]	1.1%
Akpor 2022	136	270				50.37	[44.25; 56.49]	1.1%
Tebelu 2023	206	405				50.86	[45.88; 55.83]	1.1%
Pio 2012	190	363		- <b></b> -		52.34	[47.06; 57.58]	1.1%
Simegn 2021	219	410				53.41	[48.45; 58.33]	1.1%
Kebede 2021	225	416				54.09	[49.16; 58.95]	1.1%
Lulebo 2015	214	395				54.18	[49.12; 59.17]	1.1%
Goverwa 2014	193	354				54.52	[49.17; 59.79]	1.1%
Konin 2007	110	200				55.00	[47.82; 62.02]	1.0%
Solomon 2023	223	398				56.03	[51.00; 60.97]	1.1%
Akoko 2017	124	221				56.11	[49.29; 62.76]	1.1%
Odiase 2020	64	112				57.14	[47.45; 66.45]	1.0%
lloh 2017	80	140				57.14	[48.51; 65.47]	1.0%
Nashilongo 2017	69	120		- <b>-</b>		57.50	[48.15; 66.47]	1.0%
Obirikorang 2018	397	678		-		58.55	[54.74; 62.29]	1.1%
Abeasi 2022	160	269				59.48	[53.35; 65.40]	1.1%
Attahiru 2023	165	277				59.57	[53.53; 65.40]	1.1%
Mukora-Mutseyekwa 2013	61	102				59.80	[49.63; 69.39]	1.0%
Koffi 2017	600	1000		-		60.00	[56.89; 63.05]	1.1%
Baah–Nyarkoh 2023	207	329				62.92	[57.45; 68.15]	1.1%
Abdisa 2022	253	402				62.94	[58.01; 67.67]	1.1%
Onwukwe 2022	269	422				63.74	[58.96; 68.34]	1.1%
Fekadu 2020	190	297				63.97	[58.23; 69.44]	1.1%
Jackson IL 2022	130	199				65.33	[58.27; 71.92]	1.0%
Adidja 2018	122	183				66.67	[59.33; 73.45]	1.0%
Busari 2010	163	240				67.92	[61.61; 73.78]	1.1%
Dedefo 2020	128	186				68.82	[61.63; 75.39]	1.0%
Josephs 2013	533	770		-		69.22	[65.83; 72.47]	1.1%
Ozumba 2023	285	400				71.25	[66.54; 75.64]	1.1%
Mebrahtu 2021	244	335				72.84	[67.73; 77.53]	1.1%
Achieng 2009	193	264				73.11	[67.33; 78.36]	1.1%
Kretchy 2014	323	400		-	F	80.75	[76.54; 84.50]	1.1%
Okello 2016	280	329		-	➡_	85.11	[80.79; 88.77]	1.1%
Adisa 2018	551	605			-		[88.51; 93.22]	1.1%
Buabeng 2004	119	128		· · ·		92.97	[87.07; 96.73]	1.0%
Pooled prevalence – RE model		34102		· ·		13 53	[39.44; 47.64]	100.0%
Prediction interval		0 <del>7</del> 102		~		<del>7</del> 3.32	[39.44, 47.64] [ 9.51; 81.54]	.00.0 /0
Heterogeneity: $l^2 = 98\%$ , $\tau^2 = 0.0410$ , $p =$			1		[ 0.01, 01.04]			
	-	0	20 40	60 80	100	)		